Canada to approve Natamycin TGAI and Zivion M

Date:06-04-2012


Canada's Pest Management Regulatory Agency (PMRA) has proposed full registration for the sale and use of antibiotic fungicides Natamycin TGAI and Zivion M containing the technical grade active ingredient natamycin, to suppress dry bubble disease in mushroom production.

Natamycin is naturally produced by the soil bacterium Streptomyces natalensis that inactivates germinating fungal spores. Under evaluation of available scientific information, PMRA confirmed that Zivion M can reduce the development of dry bubble disease in commercial mushrooms. It does not affect mycelial growth, and so does not negatively affect mushroom yield.

This proposal is open for public comment until 9 July, 2012.

Source: Health Canada